CA2059510C - Use of nadh and nadph as energy substitutes - Google Patents
Use of nadh and nadph as energy substitutesInfo
- Publication number
- CA2059510C CA2059510C CA002059510A CA2059510A CA2059510C CA 2059510 C CA2059510 C CA 2059510C CA 002059510 A CA002059510 A CA 002059510A CA 2059510 A CA2059510 A CA 2059510A CA 2059510 C CA2059510 C CA 2059510C
- Authority
- CA
- Canada
- Prior art keywords
- nadh
- nadph
- adenine
- nicotinamide
- reduced form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/153—Nucleic acids; Hydrolysis products or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
Abstract
Use of nicotinamide-adenine-dinucleotide in its reduced form (NADH) and/or nicotinamide-adenine-dinucleotide phosphate in its reduced form (NADPH) and/or a physiologically compatible salt thereof for energy substitution in the human or animal body, as well as a food or drink for human consumption or a feed for animal consumption having a content of said substances.
Description
I ';
Use of NADH and NADPH as energy substitutes.
The present application relates to a novel use of nicotinamide-adenine-dinucleotide in its reduced form (NADH) and/or nicotinamide-adenine-dinucleotide phosphate in its reduced form (NADPH) and/or a physiolog-ically compatible salt thereof, as well as a food or beverage for human consumption or a feed for animal consumption with a content of said substances.
For some years now, particularly in the sporting sector, the most ~aried energy-increasing products have been in favour, either in the form of the largely forbidden anabolics for increasing muscle formation, or the relatively harmless, but largely ineffective products such as sports drinks, chocolate bars, etc.
The problem of the present invention is to make available products, which act as highly effective and completely harmless energy substitutes in the human or animal body.
According to the invention this problem is solred by the use of nicotin-amide-adenine-dinucleotide in its reduced form (NADH) and/or nicotinam-ide-adenine-dinucleotide phosphate in its reduced form (NADPH) and/or a physiologically acceptable salt thereof for energy substitution in the human or animal body. According to a preferred embodiment of the invention said substances are added to a food or drink or to a feed.
Alternati~el~ the substances can also be used as the single active ingre-dient or active ingredient component in a medicament for impro~ing effi-ciency and/or for retarding deterioration and/or aging processes. A
particularly preferred use of said substances is as or in a geriatric product.
With particular preference NADH and/or NADPH and/or the physiologicallyacceptable salt thereof is administered in a quantity which supplies the human or animal body with a single dose of 0.01 to 1.0 mg/kg of body weight.
The invention also relates to a food or beverage for h~m~n consumption having a content of nicotinamide-adenine-dinucleotide in its reduced form (NADH) and/or nicotinamide-adenine-dinucleotide phosphate in its reduced form (NADPH) and/or a physiologically compatible salt thereof, said substances preferably being contained in a quantity enabling the human body to be supplied with 0.01 to 1.0 mg/kg of body weight of said substances per daily consumption unit.
Finally, the invention relates to a feed for animal consumption having a content of nicotinamide-adenine-dinucleotide in its reduced form (NADH) and/or nicotinamide-adenine-dinucleotide phosphate in its reduced form (NADPH) and/or a physiologically compatible salt thereof, said substances preferably being contained in a quantity such that the animal body is supplied with 0.01 to 1.0 mg/kg of body weight per daily consumption unit.
The "daily consumption unit" is understood to be that quantity of a food or beverage or feed, which is normally consumed every day by a specific human or animal. As NADH and NADPH are endogenic substances an increase in this quantity in individual cases is not critical, because any overdoses will not have harmful effects on the organism.
The invention is based on the finding that NADH and NADPH, apart from other energy-rich molecules such as adenine triphosphate (ATP), store in the body the energy released by energy-supplying nutrients such as carbohydrates, fats and proteins and make same available to biosynthetic processes.
The most important function of NADH is its driving force for cell resp-iration. When using oxygen NADH forms water and three ATP molecules in accordance with the following formula:
_ 3 _ 2 0 S 9 5 1 0 NADH + H +1/2 ~2 + 3 Pi + 3 ADP ~ NAD + 3 ATP + 4H20 Thus, with one NADH molecule three ATP molecules are obtained, which hare an energy of in all appro~imately 21 kilocalories. This process is called oxidative phosphorylation. The quantitative significance of this process for the human body can be demonstrated by a simple math-ematical e~ample. A person weighing 70kg requires roughly 2800 kilo-calories daily when at rest. This energy quantity can be obtained by the hydrolysis of appro~imately 384 mole of ATP corresponding to 190 kg of said substance. However, the ATP quantity present in the human body is only 50g. Therefore the organism must produce the r~ ~;ning 189.95kg every day.
The supply of NADH or NADPH makes this work much easier for the organism, because it consequently has greater energy reserves. It is also poss-ible to stimulate the many other metabolic reactions catalyzed by the two coenzymes NADH and NADPH. As ATP plays an important part in regula-ting the vascular tonus, muscle contraction, in cardiovascular functions, in neurotransmission and in thrombocyte aggregation, which are all cent-ral parameters for the weIl-being and efficiency of humans and ~n; ~lS, an increase in the number of ATP molecules by supplying NADH or NADPH
not only leads to an energy substitution, but to an improvement in the general state of health and to a retarding of deterioration and aging processes.
The use of the inventive compounds is completely harmless for the humanand animal organism, because they are endogenic substances. Thus, in clinical tests on humans up to 20 times higher concentrations were admin-istered than the indicated individual dose -~i in humans in the form of intravenous injections. No side-effects were observed. Research has shown that if the organism is supplied with too much NADH or NADPH, it is immediately o~idized to NAD or NADP and this is a reversible equilibrium reaction.
At present there is no clear picture concerning further possible action mechanisms of NADH or NADPH leading to the further positive effects on the organism described in the following description of cases.
Case Descriptions Case 1: Tennis professional, aged 24, male, was given 5mg of NADH twice weekly in tablet form. After three weeks subjective and objective incre-ase in the body efficiency and physical fitness, reduced fatigue after matches, reduced sleep requirement, increased alertness and attentive-ness.
Case 2: Manager, aged 49, male, with a fourteen hour working day, was given a chocolate bar cont~in;ng lOmg of NADPH once weekly. After taking three times there was a clear increased efficiency, reduced fatigue, able to stop drinking coffee, reduced sleep requirement, increased phys-ical and intellectual activity at the end of the working day.
Case 3: Artist, aged 70, male, uninterested in work, inactive, sleeps until noon, was given twice weekly (for consumption in one day) one litre of a refreshing drink cont~ining 15mg of NADH. After three weeks, active, energy-laden, gets up early, works all day, has a good mood and feels physically and intellectually better. After stopping NADH
administration for four weeks, a return to the previous state with the old complaints. Treatment resumed with tablets cont~ining 5mg of NADPH
twice weekly. After one week clear improvement and after fourteen days restoration of the original active well-being.
Case 4: Six year old racehorse, which had not been successful for a long time and l~cking interest in food or movement. Following a si~
week administration period of feed pellets with a content of 0.5 mg/kg of body weight per daily consumption unit, clear increase in food and movement, much fresher and more active, with a first racing success after ten weeks treatment.
The features disclosed in the description and claims can be essential to the realization of the different embodiments of the in~ention, either singly or in the form of random combinations.
Use of NADH and NADPH as energy substitutes.
The present application relates to a novel use of nicotinamide-adenine-dinucleotide in its reduced form (NADH) and/or nicotinamide-adenine-dinucleotide phosphate in its reduced form (NADPH) and/or a physiolog-ically compatible salt thereof, as well as a food or beverage for human consumption or a feed for animal consumption with a content of said substances.
For some years now, particularly in the sporting sector, the most ~aried energy-increasing products have been in favour, either in the form of the largely forbidden anabolics for increasing muscle formation, or the relatively harmless, but largely ineffective products such as sports drinks, chocolate bars, etc.
The problem of the present invention is to make available products, which act as highly effective and completely harmless energy substitutes in the human or animal body.
According to the invention this problem is solred by the use of nicotin-amide-adenine-dinucleotide in its reduced form (NADH) and/or nicotinam-ide-adenine-dinucleotide phosphate in its reduced form (NADPH) and/or a physiologically acceptable salt thereof for energy substitution in the human or animal body. According to a preferred embodiment of the invention said substances are added to a food or drink or to a feed.
Alternati~el~ the substances can also be used as the single active ingre-dient or active ingredient component in a medicament for impro~ing effi-ciency and/or for retarding deterioration and/or aging processes. A
particularly preferred use of said substances is as or in a geriatric product.
With particular preference NADH and/or NADPH and/or the physiologicallyacceptable salt thereof is administered in a quantity which supplies the human or animal body with a single dose of 0.01 to 1.0 mg/kg of body weight.
The invention also relates to a food or beverage for h~m~n consumption having a content of nicotinamide-adenine-dinucleotide in its reduced form (NADH) and/or nicotinamide-adenine-dinucleotide phosphate in its reduced form (NADPH) and/or a physiologically compatible salt thereof, said substances preferably being contained in a quantity enabling the human body to be supplied with 0.01 to 1.0 mg/kg of body weight of said substances per daily consumption unit.
Finally, the invention relates to a feed for animal consumption having a content of nicotinamide-adenine-dinucleotide in its reduced form (NADH) and/or nicotinamide-adenine-dinucleotide phosphate in its reduced form (NADPH) and/or a physiologically compatible salt thereof, said substances preferably being contained in a quantity such that the animal body is supplied with 0.01 to 1.0 mg/kg of body weight per daily consumption unit.
The "daily consumption unit" is understood to be that quantity of a food or beverage or feed, which is normally consumed every day by a specific human or animal. As NADH and NADPH are endogenic substances an increase in this quantity in individual cases is not critical, because any overdoses will not have harmful effects on the organism.
The invention is based on the finding that NADH and NADPH, apart from other energy-rich molecules such as adenine triphosphate (ATP), store in the body the energy released by energy-supplying nutrients such as carbohydrates, fats and proteins and make same available to biosynthetic processes.
The most important function of NADH is its driving force for cell resp-iration. When using oxygen NADH forms water and three ATP molecules in accordance with the following formula:
_ 3 _ 2 0 S 9 5 1 0 NADH + H +1/2 ~2 + 3 Pi + 3 ADP ~ NAD + 3 ATP + 4H20 Thus, with one NADH molecule three ATP molecules are obtained, which hare an energy of in all appro~imately 21 kilocalories. This process is called oxidative phosphorylation. The quantitative significance of this process for the human body can be demonstrated by a simple math-ematical e~ample. A person weighing 70kg requires roughly 2800 kilo-calories daily when at rest. This energy quantity can be obtained by the hydrolysis of appro~imately 384 mole of ATP corresponding to 190 kg of said substance. However, the ATP quantity present in the human body is only 50g. Therefore the organism must produce the r~ ~;ning 189.95kg every day.
The supply of NADH or NADPH makes this work much easier for the organism, because it consequently has greater energy reserves. It is also poss-ible to stimulate the many other metabolic reactions catalyzed by the two coenzymes NADH and NADPH. As ATP plays an important part in regula-ting the vascular tonus, muscle contraction, in cardiovascular functions, in neurotransmission and in thrombocyte aggregation, which are all cent-ral parameters for the weIl-being and efficiency of humans and ~n; ~lS, an increase in the number of ATP molecules by supplying NADH or NADPH
not only leads to an energy substitution, but to an improvement in the general state of health and to a retarding of deterioration and aging processes.
The use of the inventive compounds is completely harmless for the humanand animal organism, because they are endogenic substances. Thus, in clinical tests on humans up to 20 times higher concentrations were admin-istered than the indicated individual dose -~i in humans in the form of intravenous injections. No side-effects were observed. Research has shown that if the organism is supplied with too much NADH or NADPH, it is immediately o~idized to NAD or NADP and this is a reversible equilibrium reaction.
At present there is no clear picture concerning further possible action mechanisms of NADH or NADPH leading to the further positive effects on the organism described in the following description of cases.
Case Descriptions Case 1: Tennis professional, aged 24, male, was given 5mg of NADH twice weekly in tablet form. After three weeks subjective and objective incre-ase in the body efficiency and physical fitness, reduced fatigue after matches, reduced sleep requirement, increased alertness and attentive-ness.
Case 2: Manager, aged 49, male, with a fourteen hour working day, was given a chocolate bar cont~in;ng lOmg of NADPH once weekly. After taking three times there was a clear increased efficiency, reduced fatigue, able to stop drinking coffee, reduced sleep requirement, increased phys-ical and intellectual activity at the end of the working day.
Case 3: Artist, aged 70, male, uninterested in work, inactive, sleeps until noon, was given twice weekly (for consumption in one day) one litre of a refreshing drink cont~ining 15mg of NADH. After three weeks, active, energy-laden, gets up early, works all day, has a good mood and feels physically and intellectually better. After stopping NADH
administration for four weeks, a return to the previous state with the old complaints. Treatment resumed with tablets cont~ining 5mg of NADPH
twice weekly. After one week clear improvement and after fourteen days restoration of the original active well-being.
Case 4: Six year old racehorse, which had not been successful for a long time and l~cking interest in food or movement. Following a si~
week administration period of feed pellets with a content of 0.5 mg/kg of body weight per daily consumption unit, clear increase in food and movement, much fresher and more active, with a first racing success after ten weeks treatment.
The features disclosed in the description and claims can be essential to the realization of the different embodiments of the in~ention, either singly or in the form of random combinations.
Claims (8)
1. Use of nicotinamide-adenine-dinucleotide in its reduced form (NADH) and/or nicotinamide-adenine-dinucleotide phosphate in its reduced form (NADPH) and/or a physiologically compatible salt thereof for energy substitution in the human and animal body.
2. Use according to claim 1 as an additive to a food or drink.
3. Use according to claim 1 as an additive to a feed.
4. Use according to claim 1 as an active ingredient or active ingredient component in a medicament for improving efficiency and/or delaying deterioration and/or aging processes.
5. Use according to claim 4 as or in a geriatric product.
6. Use according to one of the claims 2 to 5, characterized in that NADH and/or NADPH and/or the physiologically compatible salt thereof is administered in a quantity giving the animal or human body a single dose of 0.01to 1.0 mg/kg of body weight.
7. Food or beverage for human consumption with a content of nicotinamide-adenine-dinucleotide in its reduced form (NADH) and/or nicotinamide-adenine-dinucleotide phosphate in its reduced form (NADPH) and/or a physiologically compatible salt thereof, said substances being contained in a quantity providing the human body with 0.01 to 1.0 mg/kg of body weight thereof per daily consumption unit.
8. Feed for animal consumption with a content of nicotinamide-adenine-dinucleotide in its reduced form (NADH) and/or nicotinamide-adenine-dinucleotide phosphate in its reduced form (NADPH) and/or a physiologically compatible salt thereof, said substances being contained in a quantity supplyingthe animal body with 0.01 to 1.0 mg/kg of body weight per daily consumption unit.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4102240A DE4102240C1 (en) | 1991-01-24 | 1991-01-24 | |
| DEP4102240.8 | 1991-01-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2059510A1 CA2059510A1 (en) | 1992-07-25 |
| CA2059510C true CA2059510C (en) | 1997-06-10 |
Family
ID=6423720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002059510A Expired - Fee Related CA2059510C (en) | 1991-01-24 | 1992-01-16 | Use of nadh and nadph as energy substitutes |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0496479B1 (en) |
| JP (1) | JP2533709B2 (en) |
| AT (1) | ATE112664T1 (en) |
| AU (1) | AU663479B2 (en) |
| BR (1) | BR9200207A (en) |
| CA (1) | CA2059510C (en) |
| DE (2) | DE4102240C1 (en) |
| DK (1) | DK0496479T3 (en) |
| ES (1) | ES2061313T3 (en) |
| FI (1) | FI920323A (en) |
| HU (1) | HU9200213D0 (en) |
| IE (1) | IE69861B1 (en) |
| NO (1) | NO304672B1 (en) |
| ZA (1) | ZA92275B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2735293A1 (en) * | 1995-01-17 | 1996-07-18 | Menuco Corp. | Nadh and nadph therapeutic agents for dermal administration |
| US5712259A (en) * | 1996-04-22 | 1998-01-27 | Birkmayer Pharmaceuticals | NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome |
| US5668114A (en) * | 1996-05-08 | 1997-09-16 | Birkmayer Pharmaceuticals | NADH and NADPH pharmaceuticals for treating hypertension |
| IT1318565B1 (en) * | 2000-06-09 | 2003-08-27 | World Pharma Tech Ltd | NADH OCTOCOSANOL EVITAMIN E PROENERGETIC FOOD SUPPLEMENT |
| US20040126751A1 (en) * | 2002-12-27 | 2004-07-01 | Birkmayer Jorg G.D. | Method of prolonging the life-span of living cells using NADH, NADPH and ADP-ribose |
| DE102008010245B4 (en) * | 2008-02-20 | 2011-02-10 | Emag Holding Gmbh | Method for grinding wavy workpieces |
| DE102014103443A1 (en) * | 2014-03-13 | 2015-09-17 | Jürgen Ruhlmann | Composition for use in the treatment of fatigue, lack of concentration, withdrawal symptoms, headaches and colds, in particular loss of power, hangover and fatigue |
| WO2020021734A1 (en) * | 2018-07-26 | 2020-01-30 | オリジンバイオテクノロジー株式会社 | Functional chicken eggs and method for producing same |
| DE202022000567U1 (en) | 2022-03-06 | 2022-03-16 | Penta Phi Eg | Liposomal formulation |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3594475A (en) * | 1968-04-24 | 1971-07-20 | Kyowa Hakko Kogyo Kk | Method of treating and preventing the side effects of antibiotics |
| EP0107161B1 (en) * | 1982-10-26 | 1989-08-09 | CTA Finanz AG | Device and process for optimising the tissue mass of organs within the genetic fluctuation range in humans and animals |
| IT1162938B (en) * | 1983-08-26 | 1987-04-01 | Dino Spisni | COMPOSITION FOR THE TREATMENT OF MALIGNANT CANCERS, IN PARTICULAR ON ANIMALS |
| JPS60126220A (en) * | 1983-12-09 | 1985-07-05 | Otsuka Pharmaceut Factory Inc | Nucleic acid component composition |
| ES2007350A6 (en) * | 1987-05-29 | 1989-06-16 | Ganadera Union Ind Agro | Food products enriched with nucleosides and/or nucleotides and preparation thereof. |
| JP2736103B2 (en) * | 1988-03-01 | 1998-04-02 | ヴァルター・ビルクマイヤー | Pharmaceutical for treating Parkinson's syndrome and method for producing the same |
| AT397201B (en) * | 1988-06-03 | 1994-02-25 | Birkmayer Joerg Ddr | USE OF THE ENZYME COFACTOR NADPH IN THE PRODUCTION OF A MEDICINAL PRODUCT |
-
1991
- 1991-01-24 DE DE4102240A patent/DE4102240C1/de not_active Expired - Lifetime
- 1991-12-27 JP JP3345766A patent/JP2533709B2/en not_active Expired - Fee Related
-
1992
- 1992-01-06 ES ES92250002T patent/ES2061313T3/en not_active Expired - Lifetime
- 1992-01-06 DK DK92250002.0T patent/DK0496479T3/en active
- 1992-01-06 DE DE59200603T patent/DE59200603D1/en not_active Expired - Fee Related
- 1992-01-06 EP EP92250002A patent/EP0496479B1/en not_active Expired - Lifetime
- 1992-01-06 AT AT92250002T patent/ATE112664T1/en not_active IP Right Cessation
- 1992-01-14 ZA ZA92275A patent/ZA92275B/en unknown
- 1992-01-16 CA CA002059510A patent/CA2059510C/en not_active Expired - Fee Related
- 1992-01-23 IE IE920198A patent/IE69861B1/en not_active IP Right Cessation
- 1992-01-23 AU AU10392/92A patent/AU663479B2/en not_active Ceased
- 1992-01-23 HU HU9200213A patent/HU9200213D0/en unknown
- 1992-01-23 NO NO920315A patent/NO304672B1/en not_active IP Right Cessation
- 1992-01-23 BR BR929200207A patent/BR9200207A/en not_active Application Discontinuation
- 1992-01-24 FI FI920323A patent/FI920323A/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0496479B1 (en) | 1994-10-12 |
| JPH05262652A (en) | 1993-10-12 |
| FI920323A (en) | 1992-07-25 |
| DK0496479T3 (en) | 1995-04-18 |
| ZA92275B (en) | 1992-12-30 |
| NO920315D0 (en) | 1992-01-23 |
| CA2059510A1 (en) | 1992-07-25 |
| DE4102240C1 (en) | 1992-04-09 |
| NO920315L (en) | 1992-07-27 |
| NO304672B1 (en) | 1999-02-01 |
| ES2061313T3 (en) | 1994-12-01 |
| JP2533709B2 (en) | 1996-09-11 |
| AU1039292A (en) | 1992-07-30 |
| DE59200603D1 (en) | 1994-11-17 |
| ATE112664T1 (en) | 1994-10-15 |
| IE69861B1 (en) | 1996-10-16 |
| FI920323A0 (en) | 1992-01-24 |
| AU663479B2 (en) | 1995-10-12 |
| IE920198A1 (en) | 1992-07-29 |
| HU9200213D0 (en) | 1992-04-28 |
| BR9200207A (en) | 1992-10-06 |
| EP0496479A1 (en) | 1992-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Westerfeld et al. | Metabolism and caloric value of alcohol | |
| USRE43029E1 (en) | Process for preparing a creatine heterocyclic acid salt and method of use | |
| CN100502692C (en) | Physical recovery healthy food and preparation process thereof | |
| AU685565B2 (en) | Creatine beverage and producing process thereof | |
| US8518455B2 (en) | Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and ribose | |
| US20090104171A1 (en) | Metabolic Enhancement Therapy | |
| CN1272790A (en) | Method for promoting weight and fat loss with composition comprising hydroxycitrate, carnitine and pyruvate promotor | |
| US20050271754A1 (en) | Composition for prevention or treatment of an alcohol hangover | |
| CN102448452A (en) | Dietary supplement comprising alpha keto acids for supporting diabetes therapy | |
| CA2059510C (en) | Use of nadh and nadph as energy substitutes | |
| AU782479B2 (en) | Dietary supplement energy-providing to skeletal muscles and protecting the cardiovascular tract | |
| AU750645B2 (en) | Composition comprising L-carnitine or an alkanoyl L-carnitine and NADH and/or NADPH | |
| ES2271042T3 (en) | FOOD SUPPLEMENT WITH A SLIMMING EFFECT. | |
| WO1999013739A1 (en) | Fatty acids as a diet supplement | |
| US20010020007A1 (en) | Vitamin preparations for reducing oxygen consumption during physical efforts | |
| Littman et al. | Acceleration of growth of sarcoma 180 with pyridoxamine and retardation with penicillamine. | |
| WO2005089765A1 (en) | Enzyme cofactor combination for supplementing pyruvate dehydrogenase and alpha ketogluterate dehydrogenase complexes | |
| MX2007000940A (en) | Use of methyl pyruvate for the purpose of increasing muscle energy production. | |
| CZ20003831A3 (en) | Preparation containing L-carnitine or L-carnitine alkanoyl and NADH and/or NADPH | |
| CZ5849U1 (en) | Special natural stimulant of organism | |
| MXPA00009983A (en) | Composition comprising l-carnitine or an alkanoyl l-carnitine and nadh and/or nadph |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |